I looked through the abstracts but did not see any stating that pts treated with HCQ for RA/lupus had less covid or better outcomes. I did not, however, dig through the papers. Positive HCQ data could be suppressed, as we have seen peer-reviewed literature shenanigans. Also, these studies are not prospective.
thanks for that...great search...that’s the best I’ve seen so far re: HQC trials and actual HCQ patients.
A couple studies on HCQ patients states:
60 patients:
Conclusions: In general, the outcome of the studied patients receiving HCQ was good (no deaths, no intubation needed). CYP2D6 variants could affect the outcome of Covid-19 infection.
Conclusion: There is no relationship between chronic use of hydroxychloroquine and the incidence of Covid-19.
13 patients:
COVID-19 symptoms ranged from mild to moderate, and the intensity of the symptoms was not severe enough to necessitate hospitalization. COVID-19 symptoms in RA patients included headache, fever, fatigue, dry cough, and loss of taste or smell.
Conclusions: Our findings indicated that there was no correlation between HCQ concentrations in rheumatoid arthritis patients and the occurrence of COVID-19 or its complications.
of 3817 patients - (this is a better study)
Results: 169 (4,45%) patients had Covid-19 infection, of which 12 (7.1%) died and 32 (18.9%) required hospital admission. Previous respiratory pathology was related to Covid-19 infection (P<.05). Maculopathy appears in 5.3% of patients and is significantly related to the dose of hydroxychloroquine consumed (P<.05).
Conclusion: There is no relationship between chronic use of hydroxychloroquine and the incidence of Covid-19.
not sure i understand the conclusion here.
In all these, these conclusions seem to be based on incidence of COVID, rather than results(less severe)
thanks for that research.